About Liangxing Wu
Form D filings for Synnovation Therapeutics from 2021 to 2023 list Liangxing Wu as executive officer and director.
Liangxing Wu first appears on SEC filings in 2021.
Experience
This experience comes from SEC filings. The years are when the filings name Liangxing Wu in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Liangxing Wu works with at each company, as listed on that company's latest Form D.
Synnovation Therapeutics, Inc. · Form D/A, Dec 21, 2023
